NEKTAR THERAPEUTICS 8-K

What Happened Nektar Therapeutics (NKTR) filed an 8-K (Item 5.07) on June 5, 2026 reporting results from its Annual Meeting held June 4, 2026. Howard W. Robin was elected to the Board to serve until the 2029 annual meeting. Shareholders also approved an amendment to the Amended and Restated 2017 Performance Incentive Plan increasing the authorized pool by 3,000,000 shares, ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved the non‑binding advisory vote on executive compensation (say-on-pay).

Key Details

• Director election: Howard W. Robin — For: 13,164,879; Against: 4,975,288; Abstain: 286,175; Broker non-votes: 4,588,835. Other continuing directors: Jeffrey Ajer, Diana Brainard, Robert Chess, R. Scott Greer, Roy Whitfield.
• Incentive plan increase: Amendment approved to add 3,000,000 shares to the 2017 Performance Incentive Plan — For: 13,160,661; Against: 4,902,925; Abstain: 362,756; Broker non-votes: 4,588,835.
• Auditor ratification: Ernst & Young LLP ratified for fiscal 2026 — For: 22,591,556; Against: 118,592; Abstain: 305,029.
• Say-on-pay (advisory): Approved — For: 18,154,226; Against: 161,005; Abstain: 111,111; Broker non-votes: 4,588,835.

Why It Matters These votes affect governance and shareholder economics. Electing a director shapes board composition and oversight; the 3,000,000‑share increase expands the pool available for equity awards, which can dilute existing holders over time as grants are issued. Ratifying the auditor maintains audit continuity for fiscal 2026. The advisory approval of executive compensation signals shareholder support for management pay policies, though it is non-binding. Investors should note the presence of sizable broker non‑votes on several items, which can influence outcomes where broker voting authority is limited.